Health
Simple blood test diagnoses Parkinson's disease long before symptoms appear — A new research report appearing in the December issue of the FASEB Journal (http://www.fasebj.org) shows how scientists from the United Kingdom have developed a simple blood test to…
Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
Where am I? > Home > News > Health

Monitoring of high-risk medications unchanged despite FDA warnings

Science Centric | 13 January 2010 11:55 GMT
Printable version A clip for your blog or website E-mail the story to a friend
Bookmark or share the story on your social network Vote for this article Decrease text size Increase text size
DON'T MISS —
An emergency brake in the brain
An emergency brake in the brain — Brain researchers at the University of Oslo in Norway have penetrated deeply into the innermost secrets of the brain to find…
Timing is everything when it comes to childhood asthma
Timing is everything when it comes to childhood asthma — Children who are born four months before the peak of cold and flu season have a greater risk of developing childhood asthma…
More Health

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

The research analysed about 109,000 Medicaid patients taking 'second generation' antipsychotic drugs, which can cause increases in blood sugar, cholesterol and significant weight gain, as well as other symptoms - significantly raising the risk of diabetes. It was done by health researchers from Oregon, Colorado, Georgia and Missouri, and just published in the Archives of General Psychiatry.

It found that most doctors never changed their level of baseline screening for blood sugar and cholesterol, despite a warning in 2003 from the FDA and two other organisations that these antipsychotic drugs could raise the risk of diabetes in a patient population that already was at higher risk for this disease.

'The existing baseline screening and ongoing monitoring of glucose and lipid levels in these patients was already pretty low, and the FDA warning really had no impact in changing that,' said Daniel Hartung, an assistant professor of pharmacy instruction in the College of Pharmacy at Oregon State University.

'The side effects that can be caused by these new types of antipsychotic medications, some of which were first approved in the 1990s, are not trivial,' Hartung said. 'Increases in blood sugar, cholesterol and body weight can lead to diabetes in some cases, and this patient group already has a problem with diabetes that's almost twice that of the general population.'

By 2003, Hartung said, enough evidence of these problems had accumulated that the FDA, along with the American Diabetes Association and the American Psychiatric Association, issued formal statements and warnings about the issue, and recommended baseline metabolic testing and ongoing monitoring for anyone beginning these medications.

In this study group - that examined more than 100,000 patients in California, Missouri and Oregon - it never happened.

There were no significant changes in the level of baseline testing for blood sugar and cholesterol. There was some movement toward one drug that posed less metabolic risk, the study found, but much of that could have been caused by the elimination in California, around the same time, of required prior authorisation for that drug.

Second-generation antipsychotic drugs, such as olanzapine, aripiprazole and others, are very powerful medications and were originally developed for treatment of schizophrenia, Hartung said. They were largely prescribed at first only by psychiatrists, but their use has now expanded widely into treatment for problems such as bipolar disorder and less serious mental health problems such as depression, and they are often administered by general practitioners.

The study noted that individuals with serious mental illness often have a higher risk of diabetes and cardiovascular disease, and as such are already a vulnerable population. Since the new drugs can significantly increase those risks, monitoring blood sugar and cholesterol is very important, experts say.

'Part of the problem may be that simply sending doctors a letter about these issues, which come up every now and then with medications, is just not getting the job done,' Hartung said. 'With this group of medications, at least, it clearly wasn't effective, and it does raise questions about whether new approaches are needed. Part of the problem may also be people moving from one doctor to another, and inaccurate assumptions about testing being made.'

'Also, changes in behaviour are always slow,' he said.

Anyone taking these medications, Hartung said, may wish to discuss with their physicians what type of metabolic screening they've had, and consider glucose and lipid testing if it has not already been done. If there are problems with high blood sugar, cholesterol or body weight, it may need to be considered by the physician in choosing the best treatment, he said.

Source: Oregon State University


Leave a comment
The details you provide on this page [e-mail address] will not be used to send unsolicited e-mail, and will not be supplied to a third party! Please note that we can not promise to give everyone a response. Comments are fully moderated. Once approved they will be posted within 24 hours.
Expand the form to leave a comment

RSS FEEDS, NEWSLETTER
Find the topic you want. Science Centric offers several RSS feeds for the News section.

Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.

Researchers at IRB Barcelona produce more data on key genes in diabetesResearchers at IRB Barcelona produce more data on key genes in diabetes

— One of the most reliable indicators to predict that a person will develop type 2 diabetes is the presence of insulin resistance. Insulin is produced in the pancreas…

Alzheimer's disease breakthroughAlzheimer's disease breakthrough

— CSIRO scientists have developed a new system to screen for compounds that can inhibit one of the processes that takes place during the progression of Alzheimer's…

Alzheimer's gene slows export of toxic amyloid-beta proteinAlzheimer's gene slows export of toxic amyloid-beta protein

— The only known genetic risk factor for Alzheimer's disease slows down the brain's ability to export a toxic protein known as amyloid-beta that is central to the…

Nanoparticles deliver their cargo, then disappearNanoparticles deliver their cargo, then disappear

— Medical researchers are looking at any number of new methods to get drugs to specific locations in the body. Some methods are efficient but less safe, while others…

Popular tags in Health: cancer · diabetes · malaria · obesity